Diabetic dimorphism according to acetylator status.

Area of Science:

• Pharmacogenetics
• Endocrinology
• Metabolic Diseases

Background:

• Acetylator status, a genetically determined metabolic trait, influences drug metabolism.
• Diabetes mellitus is a complex metabolic disorder with significant public health implications.
• Understanding factors influencing diabetes progression and complications is crucial for effective management.

Purpose of the Study:

• To investigate the prevalence of fast and slow acetylators of sulphadimidine in patients with diabetes mellitus.
• To explore the relationship between acetylator status and clinical characteristics in maturity onset diabetes.
• To assess the impact of acetylator status on insulin secretion and response to dietary treatment in diabetics.

Main Methods:

• Measurement of sulphadimidine acetylation rate in two groups of diabetic patients and normal controls.
• Comparison of clinical parameters (age at diagnosis, fasting insulin, glucose concentration) between fast and slow acetylators.
• Assessment of first-phase insulin secretion in response to intravenous glucose before and after dietary intervention.

Main Results:

• A higher proportion of fast acetylators was observed in patients with maturity onset diabetes compared to normal controls.
• Fast acetylators with maturity onset diabetes were older at diagnosis and exhibited higher fasting insulin levels.
• Fast acetylators demonstrated enhanced first-phase insulin secretion, particularly after dietary treatment.

Conclusions:

• Diabetic patients, especially those with maturity onset diabetes, are unexpectedly frequently fast acetylators.
• The observed association between fast acetylation and improved insulin secretion suggests a potential metabolic link.
• Further research is needed to determine if acetylator status influences the risk of diabetic neuropathy or other tissue damage.